Acute Endovascular Stroke Treatment
OtherOther names: Solitaire, Trevo, Embotrap, Medtronic, Stryker, Neuravi, Penumbra, Microvention
NCT Number: NCT03048292
Endovascular treatment has recently become the recommended therapy for acute stroke after the publication of five randomized trials (MR CLEAN1, ESCAPE2, EXTEND IA3, SWIFT PRIME4, REVASCAT5) in 2015 that demonstrate its efficacy. Hospitals need to adapt to these updated stroke care guidelines, and many hospitals are not appropriately equipped for neurointerventional procedures. Decreased time to treatment is associated with favorable clinical outcomes, and best practices to optimize workflow between comprehensive stroke centers and secondary hospitals have become an important area of study. This prospective study is being conducted on acute stroke cases within the Mount Sinai Health System from 1 June 2016 up until 31 December 2018. The researchers would like to evaluate how variable methods of interventional service delivery for acute stroke affect clinical measures and outcomes.
More specifically, the researchers are conducting this study in order to determine whether outcomes of neurointervention for large vessel occlusion in stroke, for patients presenting to and receiving treatment at a comprehensive stroke center, will be superior to that delivered by a mobilized intervention team at a central satellite hospital. In particular, the hypothesis is that factors affecting outcome include presentation to secondary hospital, delays with transfer including traffic conditions and time of day, and the acquisition of complex imaging within secondary hospitals.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Mount Sinai Beth Israel, New York, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Solitaire, Trevo, Embotrap, Medtronic, Stryker, Neuravi, Penumbra, Microvention
Time frame: 90 days
Time between first hospital arrival and final recanalization
Time frame: 3 months
Time of first hospital arrival to groin puncture
Time frame: 90 days
Time frame: 90 days
National Institutes of Health Stroke Scale (NIHSS) a 11-item impairment scale to evaluate neurologic outcome and degree of recovery.
Each item is scored between 0 and up to 4, (0 normal function with higher score indicating higher level of impairment. with minimum score 0 and maximum possible score 42.
Time frame: 90 days
the mRS measures degree of disability/dependence after a stroke. the mRS is a scale that runs from 0 (no symptoms) to 6 (death).
Icahn School of Medicine at Mount Sinai
Other
Reducing Disparities in Mechanical Embolectomy Access for Patients of New York City Via a Mobile Interventional Stroke Team: Systems of Care and Time-To-Treatment
Acronym: NYC MIST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00792428
Acute Cerebrovascular Accident, Acute Stroke
Boston, Massachusetts, United States
View Trial DetailsNCT01997749
Acid-Base Imbalance, Acidosis
Glostrup Municipality, Copenhagen, Denmark
View Trial DetailsNCT05065216
Acute Stroke, Brain Diseases
Fairhope, Alabama, United States
View Trial DetailsNCT02368145
Acute Stroke, Brain Diseases
New Brunswick, New Jersey, United States
View Trial Details